AMPLITUDE Trial: Niraparib Plus Abiraterone in HRR-Mutated mCSPC

The AMPLITUDE trial represents a major step forward in the evolution of precision medicine for prostate cancer, specifically addressing whether PARP inhibition can improve outcomes when introduced early in the disease course….